Elizabeth C Swift

age ~39

from San Diego, CA

Get Report

Also known as:

Betty Swift
Elizabeth Swist

Connected to:

Elizabeth Swift Phones & Addresses

San Diego, CA
Highland Park, IL
Evanston, IL
Westland, MI
Irvine, CA
Isla Vista, CA
San Marcos, CA
Ojai, CA
Del Mar, CA

Isbn (Books And Publications)

The Road to Madiun: The Indonesian Communist Uprising of 1948

view source

Author
Elizabeth A. Swift

ISBN #
0877630356

Resumes

Senior Scientist

view source

Location:

Chicago, IL

Industry:

Pharmaceuticals

Work:

Janssen Inc.
Senior Scientist
Abbvie
Senior Scientist
University of Michigan Sep 2013 - Apr 2015
Postdoctoral Researcher
Uc Irvine Jul 2008 - Jul 2013
Phd Graduate Student
Uc Santa Barbara Jun 2006 - Jun 2008
Undergraduate Researcher

Education:

Uc Irvine 2008 - 2013
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry Uc Santa Barbara 2004 - 2008
Bachelors, Bachelor of Science, Chemistry

Skills:

Organometallic Chemistry
Organic Chemistry
Organic Synthesis
Nmr
Synthetic Organic Chemistry
Chemistry
Mass Spectrometry
Spectroscopy
Teaching
Medicinal Chemistry
Uv/Vis
Gas Chromatography
Chemdraw
Ir Spectroscopy
Scientific Writing
Powerpoint
Microsoft Word
Organic Reaction Mechanisms

Elizabeth Swift

view source

Director Of Operations At Supersibs!

view source

Position:

Director of Operations at SuperSibs!

Location:

Greater Chicago Area

Industry:

Non-Profit Organization Management

Work:

SuperSibs!
Director of Operations

Education:

Upper Iowa University 2005 - 2008
MPA, Health and Human Services

Elizabeth Swift

view source

Location:

United States

Elizabeth Swift

view source

Location:

United States

Name / Title

Company / Classification

Phones & Addresses

Elizabeth A. Swift
President

Buena Park Mayor's Prayer Breakfast

6650 Bch Blvd, Buena Park, CA 90621

Elizabeth Swift
President

ROTARY CLUB OF BUENA PARK
Civic/Social Association · Nonclassifiable Establishments

PO Box 5243, Buena Park, CA 90622
33 Alicante Aisle, Irvine, CA 92614

Us Patents

N-Sulfonylated Pyrazolo[3,4-B]Pyridin-6-Carboxamides And Method Of Use
view source
US Patent:

20190202823, Jul 4, 2019
Filed:

Mar 6, 2019
Appl. No.:

16/293973
Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Sunnyvale CA, US
Ann de Blieck - Mechelen, BE
International Classification:

C07D 471/04
A61K 45/06
A61K 31/5377
A61K 31/4545
C07D 519/00
A61K 31/437
A61K 31/506
Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

N-Sulfonylated Pyrazolo[3,4-B]Pyridin-6-Carboxamides And Method Of Use
view source
US Patent:

20180105522, Apr 19, 2018
Filed:

Dec 15, 2017
Appl. No.:

15/843917
Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
Ann de Blieck - Mechelen, BE
International Classification:

C07D 471/04
A61K 45/06
A61K 31/437
C07D 519/00
A61K 31/506
A61K 31/5377
A61K 31/4545
Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Novel Compounds For Treatment Of Cystic Fibrosis
view source
US Patent:

20170100386, Apr 13, 2017
Filed:

Oct 7, 2016
Appl. No.:

15/288400
Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Katja E. Conrath - Mechelen, BE
Douglas Cyr - Chapel Hill NC, US
Elsa De Lemos - Paris, FR
Gert Jules Hector De Wilde - Mechelen, BE
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Mathieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Chris Tse - Libertyville IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
International Classification:

A61K 31/4545
G01N 33/50
A61K 45/06
Abstract:

A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

N-Sulfonylated Pyrazolo[3,4-B]Pyridin-6-Carboxamides And Method Of Use
view source
US Patent:

20170101405, Apr 13, 2017
Filed:

Oct 7, 2016
Appl. No.:

15/287911
Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Em iel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
Ann de Blieck - Mechelen, BE
International Classification:

C07D 471/04
A61K 31/4545
A61K 31/437
A61K 31/506
A61K 45/06
A61K 31/5377
Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted Pyrazolo[3,4-B]Pyridin-6-Carboxylic Acids And Method Of Use
view source
US Patent:

20170101406, Apr 13, 2017
Filed:

Oct 7, 2016
Appl. No.:

15/287922
Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V Patel - Round Lake IL, US
Mathieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
International Classification:

C07D 471/04
A61K 31/5377
C07D 519/00
A61K 31/496
A61K 31/541
A61K 31/506
A61K 45/06
A61K 31/437
Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).